1. Distinguishing IPF/UIP from the other interstitial pneumonia subtypes * On a scale of 1 to 5, with 1 meaning NOT at all confident and 5 meaning EXTREMELY confident. 12345 Currently, how confident are you in your ability to distinguish IPF/UIP from the other interstitial pneumonia subtypes? Currently, how confident are you in your ability to distinguish IPF/UIP from the other interstitial pneumonia subtypes? - 1 Currently, how confident are you in your ability to distinguish IPF/UIP from the other interstitial pneumonia subtypes? - 2 Currently, how confident are you in your ability to distinguish IPF/UIP from the other interstitial pneumonia subtypes? - 3 Currently, how confident are you in your ability to distinguish IPF/UIP from the other interstitial pneumonia subtypes? - 4 Currently, how confident are you in your ability to distinguish IPF/UIP from the other interstitial pneumonia subtypes? - 5 2. Developing individualized treatment plans * On a scale of 1 to 5, with 1 meaning NOT at all confident and 5 meaning EXTREMELY confident. 12345 Currently, how confident are you in your ability to develop individualized treatment plans to improve outcomes in patients with IPF? Currently, how confident are you in your ability to develop individualized treatment plans to improve outcomes in patients with IPF? - 1 Currently, how confident are you in your ability to develop individualized treatment plans to improve outcomes in patients with IPF? - 2 Currently, how confident are you in your ability to develop individualized treatment plans to improve outcomes in patients with IPF? - 3 Currently, how confident are you in your ability to develop individualized treatment plans to improve outcomes in patients with IPF? - 4 Currently, how confident are you in your ability to develop individualized treatment plans to improve outcomes in patients with IPF? - 5 3. Which of the following statement(s) are true regarding the clinical course of IPF? * a. Spontaneous remissions can occur b. Death from respiratory failure does not occur in IPF patients commonly c. Patients are never able to stabilize after a decline d. Onset is usually indolent 4. Which of the following therapeutic options has proven to be ineffective and not well-tolerated in patients with IPF? * a. Spontaneous remissions can occur b. Death from respiratory failure does not occur in IPF patients commonly c. Patients are never able to stabilize after a decline d. Onset is usually indolent 5. When would it be inappropriate to refer a patient with IPF to a lung transplant center? * a. DLCO < 39% b. Pulse oximetry > 90% after a 6-minute walk time c. Presence of pulmonary hypertension d. Honeycombing on HRCT 6. According to recent clinical trial data, which of the following therapeutic options had a significant difference in increased time between acute exacerbations in patients with IPF? * a. Pirfenidone b. Nintedanib c. Macitentan d. N-Acetylcysteine 7. When a patient is initially diagnosed with IPF, what is the median survival? * a. 3-6 months b. 6 -12 months c. 1-2 years d. 2-3 years Leave this field blank
